A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
Latest Information Update: 10 Nov 2022
At a glance
- Drugs GLM 101 (Primary)
- Indications Congenital disorder of glycosylation type 1A
- Focus Therapeutic Use
- Sponsors Glycomine
Most Recent Events
- 10 Nov 2022 New trial record